查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1993826

生物製藥CDMO市場：全球產業分析、市場規模、市場佔有率及預測（依生物製藥產品類型、生產技術、服務類型、企業規模、最終用戶、國家及地區分類，2025年至2032年）

Biologics CDMO Market, By Biologics Type, By Production Technology, By Service Type, By Scale of Operation, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 347 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年生物製藥 CDMO 市值為 219.7598 億美元，預計從 2025 年到 2032 年將以 9.20% 的複合年成長率成長。

生物製劑CDMO（合約研發生產機構）市場指的是為生物製藥公司提供生物製劑研發、生產和商業化支援的專業服務供應商。這些機構提供端到端的解決方案，包括細胞株開發、製程開發、分析測試和大規模生產。生物製劑CDMO利用先進的生物製程技術、自動化和品管系統，確保符合法規要求、產品一致性和生產效率。這些優勢有助於製藥公司縮短產品上市時間、降低營運複雜性並最佳化生產成本。透過提供擴充性且柔軟性的生物製藥生產解決方案，CDMO支援創新治療方法的發展，並使更多患者能夠獲得安全有效的生物製藥治療。

生物製藥CDMO市場－市場動態

生物製藥需求不斷成長

生物製藥需求的不斷成長指的是各個治療領域對創新、複雜且高價值的生物製藥療法的需求日益增加。這促使生物製藥公司將研發和生產外包給合約研發生產力機構（CDMO）。這一趨勢使CDMO能夠擴大產能、簡化運營，並提供端到端的解決方案以滿足不斷成長的市場需求。就生物製劑CDMO而言，此因素有助於加速製程開發、實現可擴展的生產以及符合監管要求的高品質生產。因此，CDMO可以縮短產品上市時間、提高產品一致性並最佳化資源利用。不斷成長的需求也推動了對先進生物製程技術、自動化和分析能力的投資，使CDMO能夠有效率地管理大規模的生產規模和更複雜的生物製劑。例如，截至2025年9月，印度製藥和生技產業的市場規模在2025會計年度約為4.71,075兆盧比（550億美元），預計到2030年，整個產業的市場規模將達到1.1,345兆盧比（1,300億美元）。這反映了強勁的市場成長和全球競爭力。過去十年，在政府支持力度加大、出口成長以及高素質勞動力的推動下，印度生物技術產業（包括生物製藥和生物相似藥）的規模從2015年的8.565兆盧比（100億美元）成長到2024年的86.9348兆盧比（1015億美元）。這些趨勢表明，在有利的政策和不斷提升的生產能力的支持下，印度在生物製劑和生物相似藥領域的地位日益鞏固。

生物製劑CDMO市場－市場區隔分析：

全球生物製劑 CDMO 市場按生物製劑類型、生產技術、服務類型、業務規模、最終用戶和地區進行細分。

根據生物製藥的類型，市場可細分為多個類別：單株抗體、重組蛋白、疫苗、基因療法和細胞療法。單株抗體因其廣泛的治療應用以及在腫瘤、自體免疫疾病和感染疾病治療領域的高需求，佔據了市場的大部分佔有率。對單株抗體的高需求表明，人們越來越需要靶向性強、療效顯著的生物製藥療法來應對複雜的疾病。生物製劑合約研發生產機構（CDMO）透過最佳化製程開發、大規模生產和嚴格的品管來滿足這一需求，從而確保單株抗體的及時供應，並確保患者能夠高效地獲得關鍵的生物療法。例如，根據美國政府預測，截至2024年，單株抗體（mAb）將成為全球成長最快的治療藥物類別之一，2023年全球mAb市場規模約2,050億美元，預計到2030年將超過3,000億美元。這反映了單株抗體在腫瘤學、自體免疫疾病和感染疾病領域的廣泛臨床應用。到2023年，已有超過120種單株抗體療法獲得核准，並透過在低收入和中等收入國家的推廣應用，擴大了全球可及性。這些趨勢表明，對生物目標療法日益成長的需求正在推動對生產能力、監管支持和加強全球合作的投資，以提高治療的可及性和改善醫療效果。

根據生產技術，市場可分為三大類：哺乳動物細胞培養、微生物發酵和植物來源表現系統。哺乳動物細胞培養技術佔據了市場的大部分佔有率，因為它能夠生產具有適當轉譯後修飾的複雜、高品質生技藥品。高效和多功能的生產技術是指能夠在保持結構和功能完整性的前提下，可靠地大量生產生技藥品。在基於哺乳動物細胞培養的生產中，這種高效性和多功能性使生技藥品合約研發生產機構（CDMO）能夠滿足日益成長的全球需求，最佳化產量，並以高精度和高重複性生產單株抗體和重組蛋白等複雜分子。例如，根據GFI歐洲組織的報告，德國植物來源食品零售市場（歐洲最大的植物來源食品市場）的總規模在2024年約為16.8億歐元，較2023年成長1.5%，較2022年成長6.8%。此外，2024年銷量達9.71億件，較2023年成長6.1%，較上年成長11.9%。同時，銷售量增加至5.12億公斤，較2023年成長7.1%，較2022年成長13.5%，顯示德國零售業對植物來源食品的需求持續強勁。這些數據凸顯了消費者對肉類、乳製品和飲料、優格和奶油等植物來源食品的市場滲透率正在不斷擴大。

生物製劑CDMO市場－區域洞察

生物製劑CDMO市場受生物製藥生產能力、法規結構和技術應用差異的影響，呈現明顯的區域性差異。北美市場發展穩健，這得益於其完善的生物製劑生產基礎設施、強勁的研發投入以及對合約開發和生產服務（尤其是美國和加拿大）的旺盛需求。歐洲市場持續成長，這主要得益於生物製劑生產投資的增加、有利的監管政策以及先進生產技術的應用。亞太地區市場快速擴張，其動力來自生物製藥產量的成長、醫療保健支出的增加、龐大的病患群體以及中國、印度、日本和韓國等國政府為促進生物製藥發展而採取的各項措施。相較之下，拉丁美洲和中東及非洲市場則在生物製造能力的提升、監管環境的現代化以及生物製藥開發和生產服務外包業務的增加等方面，正逐步增強其市場佔有率。

美國生物製藥CDMO市場—各國概況

美國生物製藥CDMO市場正經歷穩定成長，這主要得益於強大的生物製藥生態系統以及生物製藥研發和生產外包的日益普及。生物製藥公司擴大與CDMO合作，以縮短藥物研發週期、提升生產能力並確保符合監管要求。領先CDMO的積極進入，以及支持生物製藥創新和生產的政策，持續推動市場擴張。此外，對成本效益高的擴充性和高品質生物製藥生產的日益重視，進一步加速了CDMO在各個治療領域和商業開發平臺的應用。例如，根據DCAT 2024年1月發布的報告，預計到2028年，整個CDMO市場將以7.29%的年均複合成長率成長，其中生物製藥CDMO行業預計將從2023年的151億美元成長到2028年底的270億美元，複合年成長率（CAGR）為12.3%。這是由生物技術公司產品線的擴張以及對複雜生物製藥和細胞及基因治療服務日益成長的需求所驅動的，凸顯了持續的投資和外包趨勢如何塑造生物和製藥行業的外包環境。

目錄

第1章：生物製藥CDMO市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：生物製藥CDMO的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：生物製藥CDMO產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：生物製藥CDMO市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：生物製藥CDMO市場現狀

  • 2024年生物製藥CDMO市佔分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：生物製藥CDMO市場：依生物製藥類型分類

  • 概述
    • 細分市場佔有率分析：依生物製藥類型分類
    • 細胞和基因治療
    • 單株抗體
    • 重組蛋白
    • 疫苗

第8章：生物製藥CDMO市場：依生產技術分類

  • 概述
    • 細分市場佔有率分析：依製造技術分類
    • 植物來源的表達系統
    • 哺乳動物細胞培養
    • 微生物發酵

第9章：生物製藥CDMO市場：依服務類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按服務類型
    • 分析與發展
    • 臨床生產
    • 商業生產
    • 製程開發
    • 品管測試

第10章：生物製藥CDMO市場：依企業規模分類

  • 概述
    • 細分市場佔有率分析：依企業規模分類
    • 大規模
    • 中號
    • 小規模小規模

第11章：生物製藥CDMO市場：以最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 學術機構
    • 製藥公司
    • 生技公司

第12章：生物製藥CDMO市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第13章：主要供應商分析：生物製藥CDMO產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • AbbVie Inc.
    • AGC Biologics
    • Avid Bioservices
    • Binex Co. Ltd.
    • Bioreliance
    • Bora Pharmaceuticals Co. Ltd.
    • Catalent
    • Eurofins Scientific
    • Evonik Industries AG
    • Fujifilm Diosynth Biotechnologies
    • KBI Biopharma
    • Lonza
    • Recipharm
    • Rentschler Biopharma SE
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • WuXi AppTec
    • 3P Biopharmaceuticals SLU
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV6177

Biologics CDMO Market size was valued at US$21,975.98 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

The Biologics CDMO (Contract Development and Manufacturing Organization) Market refers to specialized service providers that assist biopharmaceutical companies in the development, manufacturing, and commercialization of biologic drugs. These organizations offer end-to-end solutions, including cell line development, process development, analytical testing, and large-scale manufacturing. Biologics CDMOs leverage advanced bioprocessing technologies, automation, and quality management systems to ensure regulatory compliance, product consistency, and efficiency. They help accelerate time-to-market, reduce operational complexity, and optimize production costs for pharmaceutical developers. By providing scalable and flexible biologics manufacturing solutions, CDMOs support the growth of innovative therapies, enabling broader access to safe and effective biologic treatments.

Biologics CDMO Market- Market Dynamics

Increasing Demand for Biologics

Increasing demand for biologics refers to the growing need for innovative, complex, and high-value biologic therapies across therapeutic areas, which drives biopharmaceutical companies to outsource development and manufacturing to Contract Development and Manufacturing Organizations (CDMOs). This trend enables CDMOs to expand production capacity, streamline operations, and offer end-to-end solutions that meet rising market demand. In the Biologics CDMO context, this driver supports accelerated process development, scalable manufacturing, and high-quality regulatory-compliant production. Consequently, CDMOs are able to reduce time-to-market, improve product consistency, and optimize resource utilization. Increasing demand also drives investment in advanced bioprocessing technologies, automation, and analytical capabilities, allowing CDMOs to manage larger production volumes and more complex biologics efficiently. For instance, in September 2025, the Indian pharmaceutical and biotech sector was valued at approximately Rs. 4,71,075 crore (US$ 55 billion) in FY25, and the broader industry is forecast to reach Rs. 1,13,450 crore (US$ 130 billion) by 2030, reflecting strong market growth and global competitiveness. Over the past decade, the Indian biotech industry, encompassing biologics and biosimilars, expanded from Rs. 85,650 crore (US$ 10 billion) in 2015 to Rs. 869,348 crore (US$ 101.5 billion) in 2024, driven by increasing government support, exports, and a skilled workforce. These developments illustrate the nation's strengthening position in the biologics and biosimilars space, supported by favorable policies and advancing manufacturing capabilities.

Biologics CDMO Market- Segmentation Analysis:

The Global Biologics CDMO Market is segmented on the basis of Biologics Type, Production Technology, Service Type, Scale of Operation, End User, and Region.

The market is divided into several categories based on biologic type: monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. The Monoclonal Antibodies segment accounts for a significant portion of the market due to its wide therapeutic applications and high demand across oncology, autoimmune, and infectious disease treatments. High demand for monoclonal antibodies refers to the increasing need for targeted and effective biologic therapies that address complex diseases. In Biologics CDMOs, addressing this demand is achieved through optimized process development, high-capacity production, and stringent quality control, enabling timely availability of monoclonal antibodies and ensuring patients have access to critical biologic therapies efficiently. For instance, in 2024, according to the US Government, monoclonal antibodies (mAbs) have become one of the fastest-growing classes of therapeutic agents globally, with the global mAb market valued at approximately USD 205 billion in 2023 and projected to reach over USD 300 billion by 2030, reflecting widespread clinical adoption across oncology, autoimmune diseases, and infectious diseases. By 2023, over 120 monoclonal antibody therapies were approved, with expansion into low- and middle-income countries boosting global access. These trends highlight that growing demand for targeted biologic therapies is driving increased investment in manufacturing capacity, regulatory support, and global collaboration to enhance accessibility and health outcomes.

The market is divided into three categories based on production technology: mammalian cell culture, microbial fermentation, and plant-based expression systems. The Mammalian Cell Culture segment accounts for a significant portion of the market due to its ability to produce complex and high-quality biologics with proper post-translational modifications. High efficiency and versatility in production refer to the capability of a technology to reliably generate large quantities of biologics while maintaining structural and functional integrity. In mammalian cell culture-based production, this efficiency and versatility allow biologics CDMOs to meet growing global demand, optimize yields, and produce complex molecules such as monoclonal antibodies and recombinant proteins with high precision and reproducibility. For instance, in 2024, according to the GFI Europe Organization report, the total plant-based food retail market in Germany, Europe's largest plant-based market, was valued at approximately €1.68 billion, marking a 1.5% increase over 2023 and a 6.8% rise compared with 2022. Additionally, unit sales reached 971 million in 2024, up 6.1% from 2023 and 11.9% relative, while sales volume climbed to 512 million kg, an increase of 7.1% versus 2023 and 13.5% versus 2022, demonstrating a continued rise in underlying demand for plant-based foods in the German retail sector. These figures highlight growing consumer engagement with plant-based options across meat, milk and drinks, yogurt, and cream categories, reflecting expanding market adoption driven by affordability and changing dietary preferences.

Biologics CDMO Market- Geographical Insights

The Biologics CDMO Market exhibits clear regional variation, shaped by differences in biopharmaceutical manufacturing capacity, regulatory frameworks, and technology adoption. North America shows steady adoption, supported by well-established biologics manufacturing infrastructure, robust R&D investment, and high demand for contract development and manufacturing services, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by increasing investment in biologics production, supportive regulatory policies, and adoption of advanced manufacturing technologies. Asia Pacific is expanding rapidly, fueled by growing biopharmaceutical production, rising healthcare expenditure, large patient populations, and government initiatives promoting biologics development in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are gradually strengthening their market presence, supported by improving biomanufacturing capabilities, regulatory modernization, and growing outsourcing of biologics development and production services.

United States Biologics CDMO Market - Country Insights

The United States Biologics CDMO market is experiencing steady growth, driven by a robust biopharmaceutical ecosystem and increasing outsourcing of biologics development and manufacturing. Biopharmaceutical companies are increasingly partnering with CDMOs to accelerate drug development timelines, enhance manufacturing capacity, and ensure regulatory compliance. Strong participation from leading contract development and manufacturing organizations, along with supportive policies that promote biopharmaceutical innovation and production, continues to encourage market expansion. Additionally, growing emphasis on cost-effective scalability and high-quality biologics production is further accelerating adoption across therapeutic and commercial development pipelines. For instance, in January 2024, according to the DCAT organization , the overall CDMO market is expected to grow at an annualized rate of 7.29% through 2028, with the biologics CDMO sector projected to expand from $15.1 billion in 2023 to $27.0 billion by the end of 2028 at a 12.3% CAGR, driven by expanding biotech pipelines and growing demand for complex biologics and cell- and gene-therapy services, underscoring how sustained investment and outsourcing trends are shaping the bio/pharma outsourcing landscape.

Biologics CDMO Market- Competitive Landscape:

The Biologics CDMO market is moderately concentrated, with several leading contract development and manufacturing organizations driving competition. Key players include 3P Biopharmaceuticals S.L.U., AGC Biologics, Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd., Evonik Industries AG, Rentschler Biopharma SE, Lonza, Samsung Biologics, WuXi AppTec, Catalent, Fujifilm Diosynth Biotechnologies, Recipharm, KBI Biopharma, Avid Bioservices, AbbVie Inc., Bioreliance, Thermo Fisher Scientific Inc., and Eurofins Scientific. These companies compete by providing comprehensive biologics development and manufacturing services, including cell line development, process development, clinical and commercial manufacturing, and quality control. For example, in 2024, Lonza expanded its biologics manufacturing capabilities by integrating continuous bioprocessing technologies, enabling higher production efficiency and reduced timelines for complex therapies. The market is driven by increasing demand for innovative biologic therapies, including monoclonal antibodies, recombinant proteins, and gene and cell therapies. Additionally, CDMOs are broadening their service offerings to include advanced analytical testing, regulatory support, and scalable manufacturing solutions to meet the evolving needs of biopharmaceutical companies and accelerate global access to high-quality therapies.

Recent Developments:

In July 2024, Bora Pharmaceuticals Co. Ltd announced a strategic collaboration with a leading biopharmaceutical innovator to expand its biologics CDMO capabilities and accelerate process development for complex biologic therapies. This initiative demonstrates Bora Pharmaceuticals' commitment to leveraging cutting-edge technologies to enhance manufacturing efficiency and support faster drug development timelines, potentially setting a new benchmark in the contract development and manufacturing space. The partnership is set to utilize advanced bioprocessing platforms and integrated analytics, positioning Bora Pharmaceuticals as a leader in high-performance biologics solutions.

In January 2025, Evonik Industries AG unveiled a major expansion of its biologics CDMO services through a collaboration with global biopharma partners to implement next-generation cell culture and purification technologies. This effort highlights Evonik's focus on deploying innovative manufacturing solutions to improve product quality, reduce production timelines, and meet growing demand for complex biologic therapies. The initiative reinforces Evonik's role as a key provider of advanced biologics manufacturing services and strengthens its competitive position in the evolving CDMO market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • AGC Biologics
  • Avid Bioservices
  • Binex Co. Ltd.
  • Bioreliance
  • Bora Pharmaceuticals Co. Ltd.
  • Catalent
  • Eurofins Scientific
  • Evonik Industries AG
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • Recipharm
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
  • 3P Biopharmaceuticals S.L.U.
  • Others

GLOBALBIOLOGICS CDMO MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Cell and Gene Therapies
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines

GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCTION TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Plant-based Expression Systems
  • Mammalian Cell Culture
  • Microbial Fermentation

GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Analytical Development
  • Clinical Manufacturing
  • Commercial Manufacturing
  • Process Development
  • Quality Control Testing

GLOBAL BIOLOGICS CDMO MARKET, BY SCALE OF OPERATION- MARKET ANALYSIS, 2019 - 2032

  • Large Scale
  • Medium Scale
  • Small Scale

GLOBAL BIOLOGICS CDMO MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Academic Institutions
  • Pharmaceutical Companies
  • Biotechnology Companies

GLOBAL BIOLOGICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics CDMO Market Snippet by Biologics Type
    • 2.1.2. Biologics CDMO Market Snippet by Production Technology
    • 2.1.3. Biologics CDMO Market Snippet by Service Type
    • 2.1.4. Biologics CDMO Market Snippet by Scale of Operation
    • 2.1.5. Biologics CDMO Market Snippet by End User
    • 2.1.6. Biologics CDMO Market Snippet by Country
    • 2.1.7. Biologics CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics CDMO Key Market Trends

  • 3.1. Biologics CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics CDMO Market Opportunities
  • 3.4. Biologics CDMO Market Future Trends

4. Biologics CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics CDMO Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics CDMO Market Landscape

  • 6.1. Biologics CDMO Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics CDMO Market - By Biologics Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biologics Type, 2024&2032 (%)
    • 7.1.2. Cell and Gene Therapies
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Recombinant Proteins
    • 7.1.5. Vaccines

8. Biologics CDMO Market - By Production Technology

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Production Technology, 2024&2032 (%)
    • 8.1.2. Plant-based Expression Systems
    • 8.1.3. Mammalian Cell Culture
    • 8.1.4. Microbial Fermentation

9. Biologics CDMO Market - By Service Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Service Type, 2024&2032 (%)
    • 9.1.2. Analytical Development
    • 9.1.3. Clinical Manufacturing
    • 9.1.4. Commercial Manufacturing
    • 9.1.5. Process Development
    • 9.1.6. Quality Control Testing

10. Biologics CDMO Market - By Scale of Operation

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Scale of Operation, 2024&2032 (%)
    • 10.1.2. Large Scale
    • 10.1.3. Medium Scale
    • 10.1.4. Small Scale

11. Biologics CDMO Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
    • 11.1.2. Academic Institutions
    • 11.1.3. Pharmaceutical Companies
    • 11.1.4. Biotechnology Companies

12. Biologics CDMO Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Biologics CDMO Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Biologics CDMO Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Biologics CDMO Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. PhilippinesMarket Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Biologics CDMO Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Biologics CDMO Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Biologics CDMO Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. AbbVie Inc.
    • 13.2.2. AGC Biologics
    • 13.2.3. Avid Bioservices
    • 13.2.4. Binex Co. Ltd.
    • 13.2.5. Bioreliance
    • 13.2.6. Bora Pharmaceuticals Co. Ltd.
    • 13.2.7. Catalent
    • 13.2.8. Eurofins Scientific
    • 13.2.9. Evonik Industries AG
    • 13.2.10. Fujifilm Diosynth Biotechnologies
    • 13.2.11. KBI Biopharma
    • 13.2.12. Lonza
    • 13.2.13. Recipharm
    • 13.2.14. Rentschler Biopharma SE
    • 13.2.15. Samsung Biologics
    • 13.2.16. Thermo Fisher Scientific Inc.
    • 13.2.17. WuXi AppTec
    • 13.2.18. 3P Biopharmaceuticals S.L.U.
    • 13.2.19. Others

14. 360 Degree AnalystView

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us